
Bavarian Nordic punished despite upgrade
Despite an upward revision in its financial forecast, Bavarian Nordic’s stock fell by over three percent on Friday. Investment economist Per Hansen suggests the adjustment might not meet investor expectations. The Danish pharmaceutical company now anticipates annual revenue between 5.4 and 5.8 billion Danish kroner, an increase from the prior estimate of 5 to 5.3 billion. The revised forecast follows a series of deals for the company’s mpox vaccine, including a recent agreement with UNICEF for one million doses. Bavarian Nordic CEO Paul Chaplin highlighted the company’s role in addressing the outbreak in Africa. The vaccine’s popularity surged after the WHO declared a global health emergency, the second in two years due to an outbreak originating in DR Congo that has spread. Africa has recorded over 32,000 infection cases. The virus, which causes symptoms like fever and headache followed by a blistering rash, usually has a mild course but can sometimes be fatal.